摘要
Abstract
Ovarian cancer (OC) is one of the most common malignant tumors among women. It often gets high mortality rate. The tra-ditional treatment of primary debulking surgery followed by adjuvant chemotherapy (PDS-ACT) is not suitable for all ovarian cancer pa-tients, especially those with contraindication or poor condition. Recently, neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) is recommended as an alternative treatment strategy. Effective postoperative analgesia is closely related to the enhanced re-covery after surgery. If postoperative analgesia cannot be fully controlled in early stage, it may develop into chronic pain, and may also be transformed into neuropathic pain or mixed pain. Patients with NACT-IDS are affected by the chemotherapeutic drugs, resulting in changing in the clotting system, nervous system, digestive system and immune system etc. , including the changes of coagulation function, decreased sensation to pain and severe response to nausea and vomiting. So, they are different in drug dosages and related side effects, when compared with radical surgery patients. In this article, we summarized the research progress of postoperative analgesia for ovarian cancer patients with neoadjuvant chemotherapy.关键词
卵巢癌/新辅助化疗/术后镇痛/阿片类药物/非甾体类抗炎药Key words
Ovarian cancer/Neoadjuvant chemotherapy/Postoperative analgesia/Opioid drugs/Non-steroidal anti-inflammatory drugs分类
医药卫生
